Future Perspective: Vision for FGFR2b in Metastatic Gastric Cancer Care

Panelists discuss how FGFR2b-directed therapy is expected to play an increasingly prominent role in the evolving treatment landscape for metastatic gastric and gastroesophageal junction cancers. They envision a future in which biomarker-driven classification becomes the cornerstone of patient management, enabling the rational selection of targeted agents across disease stages. As clinical evidence accumulates, FGFR2b testing and treatment may transition from investigational use to a standard-of-care component.

The discussion emphasizes that the incorporation of FGFR2b therapies will depend on ongoing validation, long-term outcome data, and integration into multidisciplinary practice. Future strategies may include combination regimens pairing FGFR2b-directed agents with chemotherapy or immunotherapy, as well as adaptive trial designs to accelerate discovery. Panelists note that these innovations will require continued collaboration between academic researchers, clinicians, and industry stakeholders.

Ultimately, the panel anticipates a more refined and personalized therapeutic paradigm for gastric cancer, one that leverages molecular understanding to extend survival and improve quality of life.

In summary, panelists project that FGFR2b-directed therapy will become a key pillar of precision oncology in metastatic gastric cancer care.